

J Janne Vehreschild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5003588/publications.pdf>

Version: 2024-02-01

157
papers

8,770
citations

57758

44
h-index

48315

88
g-index

174
all docs

174
docs citations

174
times ranked

11310
citing authors

#	ARTICLE	IF	CITATIONS
1	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
2	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV</i> ,the, 2017, 4, e349-e356.	4.7	805
3	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	9.1	528
4	Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies. <i>Clinical Infectious Diseases</i> , 2010, 50, 1387-1396.	5.8	525
5	The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. <i>European Respiratory Journal</i> , 2020, 56, 2001494.	6.7	368
6	Patients at High Risk of Invasive Fungal Infections. <i>Drugs</i> , 2008, 68, 1941-1962.	10.9	210
7	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	30.7	195
8	Forty-one recent cases of invasive zygomycosis from a global clinical registry. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 296-302.	3.0	169
9	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-1455.	1.8	169
10	Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1200-1212.	6.0	167
11	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	3.5	160
12	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017, 96, 1775-1792.	1.8	129
13	Mucormycosis treated with posaconazole: review of 96 case reports. <i>Critical Reviews in Microbiology</i> , 2013, 39, 310-324.	6.1	127
14	COVID-19 in cancer patients: clinical characteristics and outcome- an analysis of the LEOSS registry. <i>Annals of Hematology</i> , 2021, 100, 383-393.	1.8	127
15	Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. <i>Infection</i> , 2012, 40, 613-619.	4.7	118
16	Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1466-1471.	3.0	106
17	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope. <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	6.1	106
18	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	28.9	106

#	ARTICLE	IF	CITATIONS
19	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	3.5	99
20	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <i>Oncolimmunology</i> , 2016, 5, e1150399.	4.6	94
21	A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). <i>Journal of Infection</i> , 2007, 55, 445-449.	3.3	93
22	Severe Pneumonia and Human Bocavirus in Adult. <i>Emerging Infectious Diseases</i> , 2006, 12, 1614-1616.	4.3	91
23	Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2957-2963.	3.0	88
24	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2260-2267.	3.0	85
25	A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3387-3392.	3.0	84
26	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	13.7	82
27	Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5798-5803.	3.2	80
28	Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3- β -D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. <i>Clinical Microbiology and Infection</i> , 2016, 22, 862-868.	6.0	78
29	Quantitation of Azoles and Echinocandins in Compartments of Peripheral Blood by Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1815-1819.	3.2	76
30	Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 207-212.	3.2	70
31	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<sc>AGIHO</sc>). <i>Mycoses</i> , 2018, 61, 796-813.	4.0	69
32	Posaconazole concentrations in the central nervous system. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1468-1470.	3.0	68
33	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
34	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <i><sc>A</sc>sp</i> <i><sc>PCR</sc></i> assay and a galactomannan <sc>ELISA</sc> in bronchoalveolar lavage samples. <i>European Journal of Haematology</i> , 2012, 89, 120-127.	2.2	63
35	First results of the &œLean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)&œ. <i>Infection</i> , 2021, 49, 63-73.	4.7	62
36	Therapeutic Drug Monitoring of Voriconazole and Posaconazole. <i>Pharmacotherapy</i> , 2011, 31, 214-225.	2.6	58

#	ARTICLE	IF	CITATIONS
37	The German Corona Consensus Dataset (GECCO): a standardized dataset for COVID-19 research in university medicine and beyond. BMC Medical Informatics and Decision Making, 2020, 20, 341.	3.0	54
38	Survival of <sc>AIDS</sc>-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German <sc>HIV</sc> Lymphoma Cohort. British Journal of Haematology, 2015, 168, 806-810.	2.5	53
39	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	5.8	52
40	Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Annals of Hematology, 2009, 88, 121-132.	1.8	51
41	Frequently asked questions regarding SARS-CoV-2 in cancer patientsâ” recommendations for clinicians caring for patients with malignant diseases. Leukemia, 2020, 34, 1487-1494.	7.2	50
42	A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. Journal of Antimicrobial Chemotherapy, 2016, 71, 2634-2641.	3.0	49
43	Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 823-828.	2.0	47
44	Fungus-Specific CD4⁺ T Cells for Rapid Identification of Invasive Pulmonary Mold Infection. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 348-352.	5.6	47
45	FungiScope^{â„“}â” Global Emerging Fungal Infection Registry. Mycoses, 2017, 60, 508-516.	4.0	47
46	Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. European Journal of Clinical Pharmacology, 2012, 68, 987-995.	1.9	45
47	Current experience in treating invasive zygomycosis with posaconazole. Clinical Microbiology and Infection, 2009, 15, 77-81.	6.0	44
48	Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1664-1671.	3.2	44
49	Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood. Antimicrobial Agents and Chemotherapy, 2010, 54, 2928-2931.	3.2	43
50	Causes of death in HIV-infected patients from the Cologneâ”Bonn cohort. Infection, 2014, 42, 135-140.	4.7	42
51	Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection, 2015, 43, 707-714.	4.7	42
52	Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 2652-2658.	3.2	39
53	Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Annals of Hematology, 2021, 100, 1603-1620.	1.8	39
54	Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Eurosurveillance, 2012, 17, .	7.0	38

#	ARTICLE	IF	CITATIONS
55	Cervical cancer risk in women living with HIV across four continents: A multicohort study. <i>International Journal of Cancer</i> , 2020, 146, 601-609.	5.1	37
56	Posaconazole: a next-generation triazole antifungal. <i>Future Microbiology</i> , 2007, 2, 231-243.	2.0	36
57	Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19. <i>Scientific Data</i> , 2020, 7, 435.	5.3	35
58	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
59	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	1.9	34
60	Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2014, 25, 1709-1718.	1.2	34
61	Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. <i>European Radiology</i> , 2017, 27, 3275-3282.	4.5	34
62	Antifungal treatment strategies in high risk patients. <i>Mycoses</i> , 2008, 51, 46-51.	4.0	31
63	Invasive candidiasis and candidemia: from current opinions to future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 735-748.	4.1	31
64	Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 446-450.	2.5	31
65	Environmental and clinical epidemiology of <i>Aspergillus terreus</i> : data from a prospective surveillance study. <i>Journal of Hospital Infection</i> , 2011, 78, 226-230.	2.9	31
66	Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 31-49.	1.8	31
67	Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay. <i>PLoS ONE</i> , 2018, 13, e0204157.	2.5	31
68	Identification of invasive fungal diseases in immunocompromised patients by combining an <i>Aspergillus</i> specific PCR with a multifungal DNA microarray from primary clinical samples. <i>Mycoses</i> , 2015, 58, 735-745.	4.0	30
69	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	3.0	30
70	Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. <i>Epidemiology and Infection</i> , 2012, 140, 1848-1852.	2.1	29
71	Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2013, 24, 1189-1202.	1.2	29
72	Clinical Impact of Rapid Species Identification From Positive Blood Cultures With Same-day Phenotypic Antimicrobial Susceptibility Testing on the Management and Outcome of Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2020, 70, 1285-1293.	5.8	29

#	ARTICLE	IF	CITATIONS
73	Our 2015 approach to invasive pulmonary aspergillosis. <i>Mycoses</i> , 2015, 58, 375-382.	4.0	26
74	Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 331-338.	2.9	25
75	Zygomycosis ? current epidemiological aspects. <i>Mycoses</i> , 2007, 50, 50-55.	4.0	24
76	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. <i>BMC Infectious Diseases</i> , 2021, 21, 296.	2.9	24
77	Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from <i>Pneumocystis pneumonia</i> . <i>Journal of Infection</i> , 2009, 58, 227-231.	3.3	23
78	Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment. <i>Aids</i> , 2014, 28, 1783-1789.	2.2	23
79	Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. <i>Haematologica</i> , 2011, 96, 1855-1860.	3.5	22
80	Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 130-134.	2.5	22
81	Treatment of invasive candidiasis with echinocandins. <i>Mycoses</i> , 2009, 52, 476-486.	4.0	21
82	ECMM <i>Candi</i> RegA ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	4.0	19
83	Prediction of COVID-19 deterioration in high-risk patients at diagnosis: an early warning score for advanced COVID-19 developed by machine learning. <i>Infection</i> , 2021, , 1.	4.7	18
84	Liver involvement in HIV-infected patients diagnosed with syphilis. <i>Infection</i> , 2012, 40, 543-547.	4.7	17
85	Evaluation of an infectious disease consultation programme in a German tertiary care hospital. <i>Infection</i> , 2013, 41, 1121-1128.	4.7	17
86	Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 52-57.	2.4	17
87	Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant <i>Escherichia coli</i> : a prospective multicentre cohort study in haematological and oncological wards. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1013-1020.	6.0	17
88	Is there a role for polyenes in treating invasive mycoses?. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 565-570.	3.1	16
89	Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: A 6-yr analysis from the cologne cohort for neutropenic patients. <i>European Journal of Haematology</i> , 2014, 93, 400-406.	2.2	16
90	Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematologic malignancies. <i>Mycoses</i> , 2019, 62, 486-493.	4.0	16

#	ARTICLE	IF	CITATIONS
91	Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. <i>HIV Medicine</i> , 2022, 23, 895-910.	2.2	16
92	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	1.5	16
93	Anidulafungin ? state of affairs from a clinical perspective. <i>Mycoses</i> , 2007, 50, 38-43.	4.0	15
94	Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of <i>Clostridiales</i> . <i>Gut Microbes</i> , 2019, 10, 133-141.	9.8	15
95	Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. <i>Eurosurveillance</i> , 2012, 17, 20262.	7.0	15
96	Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. <i>Future Microbiology</i> , 2006, 1, 161-170.	2.0	14
97	Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. <i>International Journal of Hematology</i> , 2008, 87, 126-131.	1.6	13
98	Current issues in the clinical management of invasive aspergillosis – the AGIHO, DMykG, A-GMM and PEG web-based survey and expert consensus conference 2009. <i>Mycoses</i> , 2011, 54, e557-68.	4.0	13
99	Treatment cost development of patients undergoing remission induction chemotherapy: a pharmaco-economic analysis before and after introduction of posaconazole prophylaxis. <i>Mycoses</i> , 2014, 57, 90-97.	4.0	13
100	Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. <i>The Cochrane Library</i> , 2015, , CD007107.	2.8	13
101	Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. <i>Pharmaceutical Research</i> , 2015, 32, 2029-2037.	3.5	13
102	Domestic mould exposure and invasive aspergillosis – air sampling of <i>Aspergillus</i> spp. spores in homes of hematological patients, a pilot study. <i>Medical Mycology</i> , 2016, 54, 576-583.	0.7	13
103	Epidemiology of Surgical Site Infections With <i>Staphylococcus aureus</i> in Europe: Protocol for a Retrospective, Multicenter Study. <i>JMIR Research Protocols</i> , 2018, 7, e63.	1.0	13
104	Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 95-113.	1.8	12
105	Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany. <i>Epidemiology and Infection</i> , 2017, 145, 236-244.	2.1	12
106	Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. <i>Journal of Hospital Infection</i> , 2019, 101, 339-346.	2.9	12
107	Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, A-GMM and PEG web-based survey and expert consensus conference 2009. <i>Mycoses</i> , 2011, 54, e546-56.	4.0	11
108	Hotspots of Transmission Driving the Local Human Immunodeficiency Virus Epidemic in the Cologne-Bonn Region, Germany. <i>Clinical Infectious Diseases</i> , 2019, 68, 1539-1546.	5.8	11

#	ARTICLE	IF	CITATIONS
109	Salvage Therapy of Refractory Chronic Disseminated Candidiasis in a Patient with Acute Myeloid Leukaemia and Secondary Prophylaxis During Allogeneic Stem Cell Transplantation. <i>Mycoses</i> , 2006, 49, 42-47.	4.0	10
110	Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. <i>Supportive Care in Cancer</i> , 2011, 19, 1211-1216.	2.2	10
111	Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 228-231.	2.5	10
112	Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 130-138.	3.3	10
113	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. <i>BMC Cancer</i> , 2021, 21, 719.	2.6	10
114	Different doses of micafungin for prophylaxis of invasive fungal diseases in hematological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. <i>Transplant Infectious Disease</i> , 2014, 16, 968-974.	1.7	9
115	Estimating site costs prior to conducting clinical trials. <i>Clinical Investigation</i> , 2014, 4, 227-234.	0.0	9
116	Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. <i>Infection</i> , 2019, 47, 247-255.	4.7	9
117	Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. <i>Clinical Microbiology and Infection</i> , 2019, 25, 253.e1-253.e4.	6.0	9
118	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment. <i>HIV Medicine</i> , 2020, 21, 599-606.	2.2	9
119	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. <i>Infection</i> , 2020, 48, 723-733.	4.7	9
120	Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic. <i>Infection</i> , 2014, 42, 849-857.	4.7	8
121	A cost and resource utilization analysis of micafungin bridging for hematological high-risk patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2015, 94, 526-531.	2.2	8
122	Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis. <i>American Journal of Infection Control</i> , 2018, 46, 992-997.	2.3	8
123	As Galactomannan Disappoints, Our Quest for a Feasible Diagnostic Standard for Invasive Aspergillosis Continues. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 248-249.	5.6	8
124	The Role of Microbiota in Preventing Multidrug-Resistant Bacterial Infections. <i>Deutsches Arzteblatt International</i> , 2019, 116, 670-676.	0.9	8
125	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
126	Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?. <i>Leukemia and Lymphoma</i> , 2010, 51, 20-26.	1.3	7

#	ARTICLE	IF	CITATIONS
127	Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 379-382.	2.5	7
128	PTX3 Deficiency and Aspergillosis. <i>New England Journal of Medicine</i> , 2014, 370, 1665-1667.	27.0	7
129	Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. <i>Mycoses</i> , 2011, 54, 230-233.	4.0	6
130	HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?. <i>Infection</i> , 2019, 47, 293-300.	4.7	6
131	The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 2647-2659.	1.1	6
132	Development and validation of a simplified risk score for the prediction of critical COVID-19 illness in newly diagnosed patients. <i>Journal of Medical Virology</i> , 2021, 93, 6703-6713.	5.0	6
133	All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort. <i>Infection</i> , 2021, 50, 423.	4.7	6
134	Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases. <i>Artificial Intelligence in the Life Sciences</i> , 2021, 1, 100020.	2.2	6
135	Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1 infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials. <i>Clinical Infectious Diseases</i> , 2020, 70, 1406-1417.	5.8	5
136	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	2.5	5
137	Anidulafungin: advantage for the newcomer?. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 207-216.	3.1	4
138	Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 721-733.	1.1	4
139	Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients. <i>Medical Mycology</i> , 2021, 59, 93-101.	0.7	4
140	Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. <i>European Journal of Cancer</i> , 2021, 155, 281-290.	2.8	4
141	Making Moulds Meet Information retrieval as a basis for understanding <i>Pseudallescheria</i> and <i>Scedosporium</i> . <i>Mycoses</i> , 2011, 54, 1-4.	4.0	3
142	Pneumonia and Lung Infiltrates in Neutropenic Patients: Many Stones Unturned. <i>Annals of the American Thoracic Society</i> , 2013, 10, 493-495.	3.2	3
143	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
144	2187. Prediction of Patient Outcome During Febrile Neutropenia Despite Anti-infective Treatment Using Machine Learning Algorithms. <i>Open Forum Infectious Diseases</i> , 2019, 6, S744-S744.	0.9	2

#	ARTICLE	IF	CITATIONS
145	Pelvic cellulitis caused by <i>Raoultella planticola</i> in a neutropenic patient. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 298-301.	1.7	2
146	Association Between Prescribed Opioids and Infections in Patients With Neutropenia and Cancer. <i>JAMA Internal Medicine</i> , 2020, 180, 320.	5.1	2
147	HEnRY: a DZIF LIMS tool for the collection and documentation of biomaterials in multicentre studies. <i>BMC Bioinformatics</i> , 2020, 21, 290.	2.6	2
148	Clinical and pharmaco-economic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis. <i>Mycoses</i> , 2021, 64, 437-444.	4.0	2
149	Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001–2018. <i>Emerging Infectious Diseases</i> , 2020, 26, 2439-2443.	4.3	1
150	Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope [®]): Case Matched Analysis. <i>Blood</i> , 2014, 124, 1151-1151.	1.4	1
151	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). <i>Infection</i> , 2023, 51, 71-81.	4.7	1
152	Organmykosen auf einen Blick: Diagnostik und Therapie lebensbedrohlicher Pilzinfektionen. <i>Mycoses</i> , 2006, 49, 155-156.	4.0	0
153	Fungiscope - the Global Database for Rare Fungal Infections. <i>International Journal of Infectious Diseases</i> , 2008, 12, e283.	3.3	0
154	224. Epidemiology of Bloodstream infections in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients from 2009 to 2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S130-S130.	0.9	0
155	Antifungal Prophylaxis in Haematology. , 2009, , 449-457.		0
156	Dose Escalation of Caspofungin for Invasive Aspergillosis - A Phase II Trial. <i>Blood</i> , 2010, 116, 2309-2309.	1.4	0
157	Neutropenia. , 0, , 143-196.		0